Pitt Researchers Uncover Enzymes Key to Fat Loss and Muscle Gain

Got story updates? Submit your updates here. ›

A team of scientists at the University of Pittsburgh has uncovered a critical mechanism that could lead to safer and more effective obesity treatments. The researchers found that HDAC6 inhibitors, which can restore leptin sensitivity and reduce body weight in obese mice, work by targeting two enzymes - FAK and PYK2 - in the hypothalamus, the brain region that controls eating behavior. When these enzymes were blocked or removed, the weight-reducing effects of HDAC6 inhibitors disappeared, suggesting they are key to the process.

Why it matters

Current obesity medications have limitations, including gastrointestinal side effects and loss of lean muscle mass. Patients often regain fat after discontinuing these treatments, leaving them in worse health. The discovery of HDAC6 inhibitors as a promising alternative that primarily reduces fat mass while preserving lean tissue could be a critical advantage for long-term metabolic health.

The details

The study builds on earlier findings that HDAC6 inhibitors can restore leptin sensitivity and reduce body weight in obese mice. The new research demonstrates that these compounds act through the FAK and PYK2 enzymes in the hypothalamus. When researchers blocked or genetically removed these enzymes, the weight-reducing effect of HDAC6 inhibitors disappeared and leptin signaling was severely impaired.

• The study findings were published on February 5, 2026 in the journal Nature Communications.

What they’re saying

What’s next

Researchers hope to identify the molecule that triggers the signal from adipose tissue to the hypothalamus, which could become a novel therapeutic target. More work is also needed to optimize HDAC6 inhibitors for metabolic disorders while minimizing potential toxicity.